Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Heinzer

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2010
The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapyLars Budäus, Markus Graefen, Georg Salomon, et al.
European Urology|August 17, 2015
Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical ProstatectomyUwe Michl, Pierre Tennstedt, Lena Feldmeier, et al.
Cancers|February 13, 2025
Patient-Reported Outcome Measures and Decision Regret After Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following Radiotherapy or Focal TherapyFabian Falkenbach, Johanna Hagemann, Francesca Ambrosini, et al.
BJU International|February 13, 2010
The presence of prostate cancer on saturation biopsy can be accurately predictedSascha A Ahyai, Hendrik Isbarn, Pierre I Karakiewicz, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
International Journal of Cancer|September 19, 2015
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancersChristoph Burdelski, Sandra Kleinhans, Martina Kluth, et al.
International Journal of Molecular Sciences|April 21, 2015
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyMaria Christina Tsourlakis, Puya Khosrawi, Philipp Weigand, et al.
Experimental and Molecular Pathology|August 17, 2013
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomyKatharina Grupp, Thorsten Simon Höhne, Kristina Prien, et al.
BMC Cancer|June 2, 2018
PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancerMarie-Christine Heinrich, Cosima Göbel, Martina Kluth, et al.
Oncotarget|April 1, 2015
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyCristina Villares Zabalza, Meike Adam, Christoph Burdelski, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2010
The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapyLars Budäus, Markus Graefen, Georg Salomon, et al.
European Urology|August 17, 2015
Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical ProstatectomyUwe Michl, Pierre Tennstedt, Lena Feldmeier, et al.
Cancers|February 13, 2025
Patient-Reported Outcome Measures and Decision Regret After Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following Radiotherapy or Focal TherapyFabian Falkenbach, Johanna Hagemann, Francesca Ambrosini, et al.
BJU International|February 13, 2010
The presence of prostate cancer on saturation biopsy can be accurately predictedSascha A Ahyai, Hendrik Isbarn, Pierre I Karakiewicz, et al.
Carcinogenesis|September 23, 2015
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parametersNathaniel Melling, Erik Thomsen, Maria Christina Tsourlakis, et al.
International Journal of Cancer|September 19, 2015
Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancersChristoph Burdelski, Sandra Kleinhans, Martina Kluth, et al.
International Journal of Molecular Sciences|April 21, 2015
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomyMaria Christina Tsourlakis, Puya Khosrawi, Philipp Weigand, et al.
Experimental and Molecular Pathology|August 17, 2013
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomyKatharina Grupp, Thorsten Simon Höhne, Kristina Prien, et al.
BMC Cancer|June 2, 2018
PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancerMarie-Christine Heinrich, Cosima Göbel, Martina Kluth, et al.
Oncotarget|April 1, 2015
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyCristina Villares Zabalza, Meike Adam, Christoph Burdelski, et al.
Pageof 15